Millennium's Loss Shrinks

Updated from April 28

Millennium Pharmaceuticals ( MLNM) shares fell more than 5% Thursday after the company late Wednesday reported a narrower loss but lower-than-expected revenue in the first quarter.

The Cambridge, Mass.-based biotech company had a net loss of $40.6 million, or 13 cents a share, compared with a loss of $137.9 million, or 47 cents a share a year ago. Revenue rose to $92.6 million from $81.7 million in the year-ago period. Excluding items, the company lost 7 cents a share.

The consensus forecast was for a loss of $65 million, or 20 cents a share, on revenue of $106.9 million, according to Thomson First Call.

Shares fell 99 cents, or 5.7%, to $16.29, having touched a 52-week high of $19.87 in February.

Sales of its Velcade cancer treatment, which was approved by the Food and Drug Administration in the second quarter of last year, were $29.6 million.

Millennium also held to its previous forecast for a full-year loss of $255 million to $285 million on a GAAP basis and a $175 million to $200 million loss on a non-GAAP basis. Analysts are forecasting a loss of $175 million.

Research and development costs fell to $96.3 million from $126.8 million a year ago.

Millennium said Tuesday that it had won regulatory approval of Velcade in the European Union. Johnson & Johnson ( JNJ ) will market the drug outside of the U.S. with Millennium receiving royalties on sales.

More from Stocks

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

General Electric Expulsion From Dow Symbolizes Unsettled Week in Markets

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

How Small-Cap Stocks Can Protect Your Portfolio From a Trade War

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

3 Great Stock Market Sectors Millennials Should Invest In

3 Great Stock Market Sectors Millennials Should Invest In

Why Millennials Are Ditching Stocks for ETFs

Why Millennials Are Ditching Stocks for ETFs